Liposomes: Ideal drug delivery systems in breast cancer

Forouhari, Sedigheh; Beygi, Zahra; Mansoori, Zahra; Hajsharifi, Sara; Heshmatnia, Fatemeh; Gheibihayat, Seyed Mohammad

doi:10.1002/bab.2253

Cited by 14 publications

(6 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 225 , 226 In addition, poor stability needs to be addressed in the commercialization of liposomes. 227 , 228 The poor stability of micelles is also an important reason they are difficult to apply. Moreover, the enrichment of micelles is not great, resulting in only moderately pronounced efficacy, which is also a major limitation.…”

Section: Discussionmentioning

confidence: 99%

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Huang¹,

Zhai²,

Fan³

et al. 2023

IJN

View full text Add to dashboard Cite

Breast cancer (BC) is the most prevalent type of cancer in the world and the main reason women die from cancer. Due to the significant side effects of conventional treatments such as chemotherapy and radiotherapy, the search for supplemental and alternative natural drugs with lower toxicity and side effects is of interest to researchers. Curcumin (CUR) is a natural polyphenol extracted from turmeric. Numerous studies have demonstrated that CUR is an effective anticancer drug that works by modifying different intracellular signaling pathways. CUR's therapeutic utility is severely constrained by its short half-life in vivo, low water solubility, poor stability, quick metabolism, low oral bioavailability, and potential for gastrointestinal discomfort with high oral doses. One of the most practical solutions to the aforementioned issues is the development of targeted drug delivery systems (TDDSs) based on nanomaterials. To improve drug targeting and efficacy and to serve as a reference for the development and use of CUR TDDSs in the clinical setting, this review describes the physicochemical properties and bioavailability of CUR and its mechanism of action on BC, with emphasis on recent studies on TDDSs for BC in combination with CUR, including passive TDDSs, active TDDSs and physicochemical TDDSs.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Huang¹,

Zhai²,

Fan³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…Liposomes are the most common nanoformulation to deliver anticancer drugs, as shown in Figure . They are a lipid bilayer system comprising biocompatible and biodegradable phospholipids and cholesterol . Doxil, the first US Food and Drug Administration (FDA)-approved chemotherapeutic nanosystem to be used therapeutically, contains doxorubicin (DOX).…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…They are a lipid bilayer system comprising biocompatible and biodegradable phospholipids and cholesterol. 32 Doxil, the first US Food and Drug Administration (FDA)-approved chemotherapeutic nanosystem to be used therapeutically, contains doxorubicin (DOX). The PEGylated DOX liposomal formulation extends circulation time and prevents premature removal of the nanoformulation.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

“…Liposomes are closed vesicles composed of nontoxic cholesterol and phospholipids, which can encapsulate hydrophilic or hydrophobic drugs and can be integrated with cell membranes, good biocompatibility and biodegradability, low toxicity, high loading capacity, and large retention and permeability [ 31 ]. In the last 30 years, different optimized liposome particles, such as cationic liposomes, heat-sensitive liposomes, and pH-sensitive liposomes, have been fabricated by modifying the liposome surface through various engineering strategies.…”

Section: Single Drug-based Nanoformulations For Pain Treatmentmentioning

confidence: 99%

Nanomaterial-Based Drug Delivery Systems for Pain Treatment and Relief: From the Delivery of a Single Drug to Co-Delivery of Multiple Therapeutics

Xu,

Dong,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The use of nanomaterials in drug delivery systems for pain treatment is becoming increasingly common. This review aims to summarize how nanomaterial-based drug delivery systems can be used to effectively treat and relieve pain, whether via the delivery of a single drug or a combination of multiple therapeutics. By utilizing nanoformulations, the solubility of analgesics can be increased. Meanwhile, controlled drug release and targeted delivery can be realized. These not only improve the pharmacokinetics and biodistribution of analgesics but also lead to improved pain relief effects with fewer side effects. Additionally, combination therapy is frequently applied to anesthesia and analgesia. The co-encapsulation of multiple therapeutics into a single nanoformulation for drug co-delivery has garnered significant interest. Numerous approaches using nanoformulation-based combination therapy have been developed and evaluated for pain management. These methods offer prolonged analgesic effects and reduced administration frequency by harnessing the synergy and co-action of multiple targets. However, it is important to note that these nanomaterial-based pain treatment methods are still in the exploratory stage and require further research to be effectively translated into clinical practice.

show abstract

Liposomes: Ideal drug delivery systems in breast cancer

Cited by 14 publications

References 137 publications

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Nanomaterial-Based Drug Delivery Systems for Pain Treatment and Relief: From the Delivery of a Single Drug to Co-Delivery of Multiple Therapeutics

Contact Info

Product

Resources

About